Risk Stratification fi cation and Prognosis of Pulmonary Arterial Hypertension Associated with Congenital Heart Disease

被引:1
|
作者
Dong, Wenjie [1 ,2 ]
Hong, Zhibin [1 ]
Wang, Aqian [2 ]
Jiang, Kaiyu [2 ]
Zhu, Hai [2 ]
Zhang, Fu [2 ]
Guo, Zhaoxia [2 ]
Su, Hongling [2 ]
Cao, Yunshan [3 ]
机构
[1] First Peoples Hosp Tianshui, Dept Cardiol, Tianshui 741000, Peoples R China
[2] Gansu Prov Hosp, Pulm Vasc Dis Ctr, Dept Cardiol, Lanzhou 730000, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Heart Lung & Vessels Ctr, Chengdu 610072, Peoples R China
基金
中国国家自然科学基金;
关键词
Pulmonary hypertension; pulmonary arterial hypertension; congenital heart disease; risk strati fi cation; ADULTS;
D O I
10.32604/chd.2024.052267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Current guidelines for managing pulmonary arterial hypertension (PAH) recommend a risk stratification approach. However, the applicability and accuracy of these strategies for PAH associated with congenital heart disease (PAH-CHD) require further validation. This study aims to validate the reliability and predictive accuracy of a simplified stratification strategy for PAH-CHD patients over a three-year follow-up. Additionally, new prognostic variables are identified and novel risk stratification methods are developed for assessing and managing PAH-CHD patients. Methods: This retrospective study included 126 PAH-CHD patients. Clinical and biochemical variables across risk groups were assessed using Kruskal-Wallis and Fisher's exact tests. Independent risk factors were identified using ordered logistic regression, while Kaplan-Meier and Cox proportional hazards regression analyses evaluated their impact on all-cause mortality. A new stratification model for the PAH-CHD population was constructed based on these analyses. Results: Significant survival differences across stratified risk groups were observed (p < 0.001), validating the effectiveness of the simplified risk stratification method in PAH-CHD patients. Prothrombin activity was a strong independent predictor of adverse outcomes of PAH-CHD patients (Hazard ratio 0.95, p < 0.001, C-index 0.70). A model combining N-terminal pro-brain natriuretic peptide, prothrombin activity, albumin, and right atrial area achieved an area under the curve of 0.89 and a C-index of 0.85. Conclusions: The simplified risk stratification method is applicable to PAH-CHD patients. Prothrombin activity is a strong independent predictor of adverse outcomes. A comprehensive risk stratification approach, incorporating both established and novel biomarkers, enhances accessibility and offers predictive efficacy during follow-up for PAH-CHD patients, comparable to established models.
引用
收藏
页码:325 / 339
页数:15
相关论文
共 50 条
  • [1] Impact of triple vasodilator therapy on prognosis stratification of pulmonary arterial hypertension associated with congenital heart disease
    Luna, R.
    Segura De La Cal, T.
    Sarnago Cebada, F.
    Salguero, R.
    Arribas, F.
    Escribano Subias, P.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [2] Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)
    Ramjug, Sheila
    Billings, Catherine
    Bowater, Sarah
    Charalampopoulos, Athanasios
    Clift, Paul
    Elliot, Charlie
    Hurdman, Judith
    Jenkins, Petra
    Kiely, David
    Lewis, Robert
    Oliver, James
    Sabroe, Ian
    Condliffe, Robin
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [3] Risk stratification in pulmonary arterial hypertension associated with congenital heart disease. Results from CHALLENGE registry
    Giannakoulas, G.
    Vasiliadis, K.
    Frogoudaki, A.
    Ntellos, C.
    Tzifa, A.
    Brili, S.
    Manginas, A.
    Ntiloudi, D.
    Mousiama, T.
    Kolios, M.
    Pitsis, A.
    Giamouzis, G.
    Karvounis, H.
    Tsioufis, K.
    Rammos, S.
    EUROPEAN HEART JOURNAL, 2017, 38 : 153 - 153
  • [4] Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
    Zuckerman W.A.
    Krishnan U.
    Rosenzweig E.B.
    Current Pediatrics Reports, 2013, 1 (2) : 92 - 101
  • [5] Congenital heart disease associated pulmonary arterial hypertension
    Landzberg, Michael J.
    CLINICS IN CHEST MEDICINE, 2007, 28 (01) : 243 - +
  • [6] Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
    Krishnan, Usha
    Rosenzweig, Erika B.
    CLINICS IN CHEST MEDICINE, 2013, 34 (04) : 707 - +
  • [7] Pulmonary arterial hypertension associated with congenital heart disease
    D'Alto, Michele
    Mahadevan, Vaikom S.
    EUROPEAN RESPIRATORY REVIEW, 2012, 21 (126): : 328 - 337
  • [8] Pulmonary arterial hypertension associated with congenital heart disease
    Kulik, Tom
    Mullen, Mary
    Adatia, Ian
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2009, 27 (1-2) : 25 - 33
  • [9] Riociguat for pulmonary arterial hypertension associated with congenital heart disease
    Rosenkranz, Stephan
    Ghofrani, Hossein-Ardeschir
    Beghetti, Maurice
    Ivy, Dunbar
    Frey, Reiner
    Fritsch, Arno
    Weimann, Gerrit
    Saleh, Soundos
    Apitz, Christian
    HEART, 2015, 101 (22) : 1792 - U41
  • [10] Risk assessment tool implementation in congenital heart disease associated pulmonary arterial hypertension
    Yaylali, Y.
    Yagmur, B.
    Sinan, U. Y.
    Meric, M.
    Basarici, I.
    Kilickiran-Avci, B.
    Senol, H.
    Nalbantgil, S.
    Kucukoglu, M. S.
    Ongen, Z.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1950 - 1950